Loading
Avasopasem is Galera Therapeutics' radioprotector for the severe mouth ulcers of head and neck chemoradiation; its phase 3 trial met its main goal but the FDA asked for another study in 2023.
Avasopasem manganese is given by infusion before each radiotherapy fraction. The ROMAN phase 3 trial in head and neck cancer patients receiving cisplatin chemoradiation reduced the incidence of severe oral mucositis compared with placebo. The FDA issued a complete response letter in August 2023 asking for an additional trial before approval. A related compound, rucosopasem, is being tested to increase the effect of stereotactic radiotherapy on tumours rather than protect normal tissue.
A manganese complex that mimics the enzyme superoxide dismutase, converting the superoxide radicals that radiation creates in normal tissue into hydrogen peroxide, which healthy cells clear more easily than tumour cells.
1.Avasopasem manganese slips into a pocket on its target.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Avasopasem manganese" OR ABSTRACT:"Avasopasem manganese" OR TITLE:"GC4419" OR ABSTRACT:"GC4419") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Avasopasem manganese, not a curated reading list.
Shares Radioprotectors and normal-tissue sparing drugs, Head and neck squamous cell carcinoma and the tag radiation-wave3.
Shares Head and neck squamous cell carcinoma and the tag radiation-wave3.
Shares Head and neck squamous cell carcinoma and the tag radiation-wave3.
Shares Head and neck squamous cell carcinoma and the tag radiation-wave3.
Shares Radioprotectors and normal-tissue sparing drugs, Head and neck squamous cell carcinoma.
Shares Radioprotectors and normal-tissue sparing drugs, Head and neck squamous cell carcinoma.